MLC Malin Corp PLC

Malin Corporation plc appoints Peter Schwartzman to Senior Management Team

Malin Corporation plc. (ISE:MLC, "Malin"), an Irish-based global life sciences company, today announced the appointment of Peter Schwartzman to the company’s senior team, effective immediately.

Peter Schwartzman brings 30 years of experience in asset and risk management to Malin. He was most recently a Managing Director in the Leveraged Finance Group within BlackRock Financial Management - the world’s largest asset manager. From 1998 to 2016, Peter was a leading member of a team that managed over $40 billion of assets in credit markets.

Peter’s initial focus in Malin will be to work with and alongside a number of the current members of the senior team to further refine Malin’s capital sourcing efforts and, subsequently, how that capital is structured. A particular focus will center on aligning current and future capital to cash flow generating opportunities that may afford shareholders additional ways to participate in Malin’s total shareholder return approach to capturing value. He will report to Malin CEO, Kelly Martin and will be based in the company’s offices in New Haven, Connecticut, USA.

Peter has also previously held the role of Vice President, Corporate Bond Research Group at Alliance Capital Management in addition to analyst roles in Moody's Investors Service and J.J. Kenny. He holds an MBA from New York University, Stern School of Business.

ENDS

About Malin Corporation plc

Malin (ISE:MLC) is an Irish incorporated public limited company. Its purpose is to create shareholder value through the selective long-term application of capital and operational expertise to private, pre-IPO, pre-trade sale operating businesses in dynamic and fast growing segments of the life sciences industry. Through its operational involvement, Malin works with its investee companies to enable them to reach the full potential of their value proposition and to achieve commercial success. For more information visit www.malinplc.com

EN
07/10/2016

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Malin Corp PLC

Malin Corporation: 3 directors

Three Directors at Malin Corporation sold 61,818 shares at 9.300EUR. The significance rating of the trade was 63/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clea...

Liberum Research Team
  • Liberum Research Team

LIBERUM: Morning Comment

Research Reels: Professional Services, Commodity snapSHOT, Smith & Nephew, MJ Gleeson*, Malin Corporation*, Market Highlights

Edward Thomason ... (+2)
  • Edward Thomason
  • Seb Jantet

LIBERUM: Malin Corporation* - Prelims & tender offer price at premium

Malin has released 2022 prelims and priced the previously announced €140m tender offer at a 25% premium to the current share price. Despite a difficult biotech equity market last year, Malin performed exceptionally well in 2022 and has delivered on its strategy of crystallising value from its portfolio and returning capital to shareholders. After the tender offer, the company is left with €33m of cash, more than enough to realise further value from the portfolio and to deploy in new opportunitie...

 PRESS RELEASE

Malin Corporation plc appoints Dr. Andrew von Eschenbach, former FDA c...

DUBLIN--(BUSINESS WIRE)-- Malin Corporation plc. (ISE:MLC, "Malin"), an Irish-based global life sciences company, today announced the appointment of Dr. Andrew von Eschenbach as Chief Medical Adviser, effective immediately. Dr. von Eschenbach previously served as an advisory partner to Malin. Dr. von Eschenbach is currently the president of Samaritan Health Initiatives Inc, and serves as an adjunct professor at Houston’s University of Texas MD Anderson Cancer center. He is also a member of the Prostate Cancer Foundation Board...

 PRESS RELEASE

Malin Announces U.S. FDA Approval for New Hourglassâ„¢ Peripheral Embo...

DUBLIN--(BUSINESS WIRE)-- Malin Corporation plc. (ISE:MLC, "Malin"), an Irish based and globally operating life sciences company, today announced that its EMBA device, known as the Hourglass™ Peripheral Embolisation Plug, was granted U.S. FDA 510(k) clearance to commence marketing in the US. The Hourglass™ peripheral embolisation plug represents a breakthrough in peripheral embolisation devices in that it is designed to provide precise, secure, over-the-wire delivery and immediate occlusion with a single integrated device. ...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch